The role of cysteinyl cathepsins in venous disorders

Xian Wu Cheng; Takeshi Sasaki; Masafumi Kuzuya

doi:10.1160/TH13-10-0889

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(01): 216-218
DOI: 10.1160/TH13-10-0889

Letters to the Editor

Schattauer GmbH

The role of cysteinyl cathepsins in venous disorders

Xian Wu Cheng

¹Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

³Department of Cardiology, Yanbian University Hospital, Yanji, Jilin Province, China

⁴Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea

,

Takeshi Sasaki

²Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, Hamamatsu, Japan

,

Masafumi Kuzuya

¹Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

› Author Affiliations

Abstract

Full Text

References

References
1 Somers P, Knaapen M. The histopathology of varicose vein disease. Angiology 2006; 57: 546-555.
2 Lim CS, Qiao X, Reslan OM. et al. Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 2011; 53: 764-773.
3 Irwin C, Synn A, Kraiss L. et al. Metalloproteinase expression in venous aneurysms. J Vasc Surg 2008; 48: 1278-1285.
4 Lenglet S, Thomas A, Chaurand P. et al. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb Haemost 2012; 107: 409-416.
5 Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 2008; 23: 85-98.
6 Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg 2009; 96: 1231-1242.
7 Munger SJ, Kanady JD, Simon AM. Absence of venous valves in mice lacking Connexin37. Dev Biol 2013; 373: 338-348.
8 Kanady JD, Dellinger MT, Munger SJ. et al. Conne-xin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev Biol 2011; 354: 253-66.
9 Cheng XW, Huang Z, Kuzuya M. et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011; 58: 978-986.
10 Cheng XW, Shi GP, Kuzuya M. et al. Role for cys-teine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012; 125: 1551-1562.
11 Cheng XW, Kuzuya M, Sasaki T. et al. Increased expression of elastolytic cysteine proteases, ca-thepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004; 164: 243-251.
12 Turk V, Stoka V, Vasiljeva O. et al. Cysteine cathep-sins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012; 1824: 68-88.
13 Xu N, Zhang YY, Lin Y. et al. Increased levels of ly-sosomal cysteinyl cathepsins in human varicose veins: A histology study. Thromb Haemost 2013; 111: 333-344.
14 Hu L, Cheng XW, Song H. et al. Cathepsin K Activity Controls Injury-Related Vascular Repair in Mice. Hypertension 2014; 63: 607-615.
15 Cheng XW, Murohara T, Kuzuya M. et al. Superox-ide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008; 173: 358-369.
16 Nagai A, Ryu JK, Terashima M. et al. Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with ca-thepsin B. Brain Res 2005; 1066: 120-128.
17 Droga-Mazovec G, Bojic L, Petelin A. et al. Cys-teine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem 2008; 283: 19140-19150.
18 Mahmood DF, Jguirim-Souissi I, Khadija el H. et al. Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis. J Biol Chem 2012; 286: 28858-28866.
19 Alcalay NI, Sharma M, Vassmer D. et al. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1. Am J Physiol Renal Physiol 2008; 295: F1725-1734.
20 Tang Q, Cai J, Shen D. et al. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med 2009; 87: 249-260.
21 Yu W, Liu J, Shi MA. et al. Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice. PLoS One 2010; 05: e13973.
22 Urbich C, Heeschen C, Aicher A. et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005; 11: 206-213.
23 Cheng XW, Kikuchi R, Ishii H. et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis 2013; 228: 211-216.